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Wnt/b-catenin signal transduction requires direct
binding of b-catenin to Tcf/Lef proteins, an event
that is classically associated with stimulating tran-
scription by recruiting coactivators. This molecular
cascade plays critical roles throughout embryonic
development and normal postnatal life by affecting
stem cell characteristics and tumor formation.
Here, we show that this pathway utilizes a fundamen-
tally different mechanism to regulate Tcf7l1 (formerly
named Tcf3) activity. b-catenin inactivates Tcf7l1
without a switch to a coactivator complex by
removing it from DNA, which leads to Tcf7l1 protein
degradation. Mouse genetic experiments demon-
strate that Tcf7l1 inactivation is the only required
effect of the Tcf7l1-b-catenin interaction. Given the
expression of Tcf7l1 in pluripotent embryonic and
adult stem cells, as well as in poorly differentiated
breast cancer, these findings provide mechanistic
insights into the regulation of pluripotency and the
role of Wnt/b-catenin in breast cancer.
INTRODUCTION
Canonical Wnt/b-catenin signaling impacts a wide range of bio-
logical activities, including stem cell self-renewal, organmorpho-
genesis, and tumor formation (Clevers and Nusse, 2012; Nusse,
2012). Regulation of the pathway centers on the stability of
b-catenin, which is targeted for proteasome-mediated degrada-
tion by a complex containing adenomatous polyposis coli (APC),
Axin structural proteins, and glycogen synthase kinase 3 (GSK3)
(Stamos andWeis, 2013). Phosphorylation of b-catenin by GSK3
stimulates degradation dependent upon APC, Axin, and the
b-TrCP E3 ligase (Aberle et al., 1997; Hart et al., 1999; Yost
et al., 1996). Wnt signaling inhibits degradation of b-catenin by
blocking its ubiquitination (Li et al., 2012). PharmacologicalGSK3 inhibitors similarly inhibit b-catenin degradation by block-
ing b-catenin phosphorylation.
An important downstream mechanism of the Wnt/b-catenin
pathway occurs as b-catenin binds to the amino terminal
of Tcf/Lef proteins, thereby displacing corepressor proteins
bound to the Tcf/Lef (Cavallo et al., 1998; Daniels and Weis,
2005; Roose et al., 1998). Tcf-b-catenin binding subsequently
recruits transactivator proteins to the genomic sites that were
previously occupied by corepressors (Brannon et al., 1997;
Molenaar et al., 1996; van de Wetering et al., 1997). This
accepted model of canonical Wnt/b-catenin signaling is con-
sistent with observed effects of Tcf/Lef proteins in many
contexts (Cadigan and Waterman, 2012); however, it is not
consistent with recent observations for mammalian Tcf7l1
(formerly Tcf3). In cells where Lef1 and Tcf7 (formerly Tcf1)
act as b-catenin-dependent transactivators, only transcriptional
repressor activity for Tcf7l1 was detected (Merrill et al., 2001;
Wu et al., 2012a). Here, we show that b-catenin binding to
Tcf7l1 does not form a transactivation complex, but instead
initiates a fundamentally distinct mechanism. b-catenin binding
inactivates Tcf7l1 by reducing its chromatin occupancy and
secondarily stimulates its protein degradation. Mouse genetic
experiments demonstrate that this inactivation is the only
necessary function of the Tcf7l1-b-catenin interaction. These
molecular and genetic findings provide insights into the role
of Wnt/b-catenin signaling in cells where Tcf7l1 expression is
prominent, including embryonic stem cells (ESCs) and poorly
differentiated breast cancer.
RESULTS
b-Catenin Reduces Tcf7l1 Protein Levels by Stimulating
Protein Degradation
Molecular support for a conversion into transactivators by b-cat-
enin includes the ability of a b-catenin-Tcf7 fusion protein to acti-
vate target genes without Wnt pathway stimulation (Staal et al.,
1999). If Tcf7l1 were switched to a transactivator by b-catenin,
one would expect a b-catenin-Tcf7l1 fusion protein to similarly
activate target genes. In ESCs, the b-catenin-Tcf7l1 fusion wasCell Reports 4, 1–9, July 11, 2013 ª2013 The Authors 1
Figure 1. Wnt/b-Catenin Stimulates Tcf7l1 Protein Degradation
(A) Transient transfection of Tcf7l1/ ESCs with b-catenin-Tcf fusion plasmids and SuperTOPFlash (top) or LRH1 promoter (bottom) luciferase reporter
plasmids. Values represent mean ± SD for triplicate transfections.
(B) Western blot (top) and quantitative RT-PCR (qRT-PCR, bottom) analyses of ESCs treated with 50 ng/ml recombinant Wnt3a (left) or 3 mMCHIR (right). Values
represent mean ± SD for biological triplicates.
(C–E)Western blot analysis of ESCs treatedwith 3 mMCHIR for 24 hr inDgcr8mutant cells (C), for 6 hr withMG-132 (5 mM) in Tcf7l1+/+ and Tcf7l1DN/DN cells (D),
and for 12 hr with leptomycin B (E).
(F) Distribution of nuclear Tcf7l1 immunoreactivity levels in Tcf7l1+/+ (top) and Tcf7l1DN/DN (bottom) cells expressing either GFP (red bars) or DNb-catenin (blue
bars). A total of 200 nuclei were counted for each condition. Data are representative of three separate experiments.
See also Figure S1.unable to activate TOPFlash and LRH-1 reporters, and instead
repressed Wnt3a-stimulation of reporter genes (Figure 1A).
Rather than converting Tcf7l1 to a transactivator, Wnt/b-catenin2 Cell Reports 4, 1–9, July 11, 2013 ª2013 The Authorsstimulation notably decreased Tcf7l1 protein in ESCs treated
with recombinant Wnt3a or the GSK3 inhibitor, Chiron99021
(CHIR; Figure 1B). These results indicate a significant difference
in the downstream effects of Tcf7-b-catenin and Tcf7l1-
b-catenin interaction.
To elucidate the transactivation-independent effects of b-cat-
enin on Tcf7l1, we investigated how Tcf7l1 protein levels were
reduced. Wnt3a- and CHIR-treated ESCs displayed increased
Lef1 and Tcf7 messenger RNA (mRNA) levels that correlated
with increased protein levels (Figure 1B), consistent with Lef1
and Tcf7 being Wnt/b-catenin target genes (Filali et al., 2002;
Hovanes et al., 2000; Roose et al., 1999; Waterman, 2004). In
contrast, decreased Tcf7l1 protein was not paralleled by a signif-
icant change in mRNA levels (Figure 1B), indicating that b-cate-
nin regulation of Tcf7l1 does not occur transcriptionally. Because
Dgcr8 is a required component of the microprocessor complex,
which is necessary for biogenesis of microRNAs (Wang et al.,
2007), the CHIR-stimulated reduction of Tcf7l1 in Dgcr8/
ESCs showed that reduction of Tcf7l1 protein was also not
microRNA mediated (Figure 1C). Treatments with the protea-
some inhibitors MG-132 and MG-115 effectively blocked
the CHIR-stimulated reduction of Tcf7l1 protein (Figures 1D
and S1A), demonstrating that reduction of Tcf7l1 required
protein degradation. Finally, reduction of Tcf7l1 was blocked
by leptomycin B, indicating that it required Exportin1-mediated
nuclear transport (Figure 1E).
To determine the role of b-catenin binding to Tcf7l1, we used
Tcf7l1DN/DN knockin ESCs. In contrast to wild-type Tcf7l1,
Tcf7l1DN was not degraded in response to CHIR or Wnt3a (Fig-
ures 1D andS1B), indicating that the Tcf7l1-b-catenin interaction
was necessary for degradation. To determine whether the inter-
action was sufficient for degradation, we expressed DNb-cate-
nin in ESCs and measured the Tcf7l1 levels by quantitative
immunofluorescence. DNb-catenin expression was sufficient to
reduce nuclear Tcf7l1 levels in Tcf7l1+/+ but not in Tcf7l1DN/DN
cells (Figures 1F and S1C). Interestingly, several recent studies
showed that amutant form of b-catenin (b-cateninDC) supported
self-renewal of mouse ESCs and complemented defects caused
by ablation of b-catenin despite the lack of the C-terminal trans-
activation domain in the b-cateninDC mutant (Kelly et al., 2011;
Lyashenko et al., 2011; Wray et al., 2011). Therefore, it is notable
that expression of DNb-cateninDC was also sufficient to reduce
nuclear Tcf7l1 protein levels ESCs (Figure S1D). Given the sub-
stantial effects of altering Tcf7l1 levels in ESCs, the reduction
of Tcf7l1 protein provides a mechanism for the poorly under-
stood pro-self-renewal effects of b-cateninDC in ESCs.
Reduction of Tcf7l1 Is Sufficient to Replace
the Tcf7l1-b-Catenin Interaction
If a principal mechanism of Wnt/b-catenin signaling functions
through inactivation of Tcf7l1, and not conversion to a Tcf7l1-
b-catenin transactivator complex, reducing the level of Tcf7l1
should be sufficient to replace the Tcf7l1-b-catenin interaction.
We first tested this hypothesis in ESCs, where reducing the
amount of Tcf7l1DN by small interfering RNA (siRNA) stimulated
the reporter gene response to Wnt3a (Figures S2A and S2B). To
examine the broader effects of reducing Tcf7l1 in mice, we
reduced the level of Tcf7l1 by breeding for hemizygous mice
(i.e., Tcf7l1+/ or Tcf7l1/DN; Figure S2C). It is important to
note that Tcf7l1/ mice die shortly after gastrulation (Merrill
et al., 2004). Tcf7l1DN/DN embryos progress normally throughgastrulation, but later develop a constellation of morphogenetic
defects that result in death for all Tcf7l1DN/DNmice at or before
birth (Hoffman et al., 2013; Wu et al., 2012a). Mating Tcf7l1+/
with Tcf7l1+/DN mice produced the Mendelian-expected ratio
of Tcf7l1/DN offspring, despite the genetic absence of a
Tcf7l1 protein capable of interacting with b-catenin (Figures 2A
and S2D). Moreover, Tcf7l1/DN mice did not display any of
the morphogenetic defects observed in Tcf7l1DN/DN mice,
including poor vascular integrity, edema, oligodactyly, and
opened eyelids (Figures 2C–2D’’, S2E, and S2F). Indeed,
Tcf7l1/DNmice advanced to adulthood and appeared indistin-
guishable from Tcf7l1+/+ littermates throughout their ostensibly
normal lifetimes (Figure 2B). Thus, removing one copy of
Tcf7l1DN genetically rescued the defects caused by ablating
the Tcf7l1-b-catenin interaction. These results demonstrate
that inactivation of Tcf7l1 by b-catenin is the necessary effect
downstream of Tcf7l1-b-catenin interaction for mouse embryo-
genesis and postnatal viability.
To determine the effects of reducing Tcf7l1 at the target gene
level in mice, tissues that were previously shown to be affected
in Tcf7l1DN/DN embryos were examined in Tcf7l1-/DN embryos
harboring the BAT-Gal reporter. Compared with Tcf7l1+/+ em-
bryonic day 14.5 (e14.5) eyelids (Figures 2E–E00 0), Tcf7l1DN/DN
displayed a restricted domain of BAT-Gal activity and decreased
expression of Lef1, aWnt/b-catenin target, in themucocutaneous
junction of the eyelid (Figures 2F–2F00 0; Wu et al., 2012a). The
domain of Lef1 expression and BAT-Gal activity was increased
in Tcf7l1/DN relative to Tcf7l1DN/DN, and BAT-Gal activity
was detected only in cells expressing Lef1 (Figures 2F–2G00 0,
S2G, and S2H). Given the inability of Tcf7l1DN to respond to
b-catenin, the rescue of BAT-Gal activity in Tcf7l1-/DN embryos
shows that activation is mediated by Lef1, and attenuation of
this activation depends on the level of Tcf7l1 repressor.
b-Catenin Stimulates TCF7L1 Inactivation in Human
Breast Cancer
In addition to pluripotent cells in the early mammalian embryo,
and ESCs in vitro, TCF7L1 mRNA expression has been noted
in several types of adult stem cells and in poorly differentiated
cancers (Ben-Porath et al., 2008; Ivanova et al., 2002; Tumbar
et al., 2004). We reasoned that the aspects of the Tcf7l1-desta-
bilization mechanism could provide insights into the effects of
Wnt/b-catenin in these important contexts. Breast cancer
was chosen for further analysis because (1) Wnt/b-catenin has
been known to affect mammary tumors since it was first discov-
ered by Nusse et al. (1984), (2) despite its long history, the under-
lying mechanisms of Wnt/b-catenin’s effects in this disease
remain poorly understood (Alexander et al., 2012), (3) poorly
differentiated mammary tumors express high levels of TCF7L1
mRNA (0.81 mean TCF7L1 mRNA ± 0.91 SD for 270 basal
tumors, 0.32 ± 0.67 for 941 nonbasal tumors; p < 0.0001; Fig-
ure 3A; Ben-Porath et al., 2008), and (4) altering the level of Tcf7l1
caused significant effects in xenograft tumor-formation experi-
ments (Slyper et al., 2012).
Consistent with previous analyses, we noted a very high fre-
quency of the basal molecular subtype among invasive mam-
mary tumors expressing the highest levels of TCF7L1 mRNA
(83% of tumors with TCF7L1mRNA > 1.1 were basal, and 22%Cell Reports 4, 1–9, July 11, 2013 ª2013 The Authors 3
Figure 2. Reducing Tcf7l1 Levels Replaces the Requirement for
b-Catenin Interaction in Mice
(A–D00) Tcf7l1/DN mice appear normal at birth (A) and through adult stages
(B; see also Figure S2D). Tcf7l1/DN embryos do not develop the phenotypes
observed in Tcf7l1DN/DN embryos (i.e., oligodactyly [C–C00] and opened
eyelids at birth [D–D00]; see also Figures S2E and S2F).
(E–G00 0) Tcf/Lef-b-catenin activation of BAT-Gal reporter is restored in the
Tcf7l1/DN eyelid. Immunofluorescent staining for Tcf7l1 (green), Lef1 (red),
and b-galactosidase (blue) in e14.5 eyelids from BAT-Gal transgenics with the
indicated Tcf7l1 genotype. Arrows point to Lef1-high and Tcf7l1-low nuclei.
4 Cell Reports 4, 1–9, July 11, 2013 ª2013 The Authorsof all tumors assessed were basal; Figure 3A; Ben-Porath et al.,
2008; Slyper et al., 2012). To examine patterns of TCF7L1 protein
expression, we used a TCF7L1-specific antibody for immunohis-
tochemistry (IHC) staining of an array of breast cancer tissue
samples (Figure S3A; Khramtsov et al., 2010). In contrast to
TCF7L1 mRNA, nuclear TCF7L1 protein was not significantly
higher in basal subtype tumors (55 ± 60, n = 23) relative to non-
basal tumors (44 ± 74, n = 47; Figures 3B and S3A), and the fre-
quency of basal tumors displaying strong nuclear TCF7L1 (i.e.,
nuclear IHC score > 180) was lower than the overall frequency
of basal tumors on the array (25% with high nuclear TCF7L1
versus 32% of all tumors; Figures 3C, S3B, and S3C). Thus,
although TCF7L1 mRNA is highly elevated in basal subtype tu-
mors, TCF7L1 protein is not.
Previous analyses of b-catenin protein in patient samples
demonstrated that nuclear and cytoplasmic b-catenin was
strongly associated with basal subtype tumors and poor prog-
nosis (Geyer et al., 2011; Khramtsov et al., 2010; Lo´pez-Knowles
et al., 2010). To determine whether the disparity between
TCF7L1 mRNA and protein levels could be caused by elevated
b-catenin, we compared the TCF7L1 IHC results with the b-cat-
enin IHC results among identical patient samples. Remarkably,
tumors with strong nuclear TCF7L1 had predominantly no
nuclear or cytoplasmic b-catenin (b-catenin IHC score of 0; Fig-
ure 3D), and tumors with cytoplasmic and/or nuclear b-catenin
(b-catenin IHC score of 2 or 3) displayed predominantly diffuse
or low levels of TCF7L1 protein (Figure 3D). These data indicate
that in human mammary tumors, stimulation of Wnt/b-catenin is
strongly correlated with decreased nuclear TCF7L1.
To test for a causal relationship between b-catenin and
TCF7L1 levels in breast cancer, we used several cancer cell
lines. Endogenous TCF7L1 protein was reduced by CHIR in all
cells examined (MCF7, MDA-MB-231, MDA-MB-468, HS578T,
and HCC38; Figure 3E). As in the ESCs, TCF7L1 mRNA was
not significantly diminished (Figure S3E), and the reduction of
TCF7L1protein was blocked by the proteasome inhibitor
MG-132 (Figure S3F). Treating cells with CHIR or CHIR +
MG-132 increased the cytoplasmic levels of TCF7L1 detected
by immunofluorescence (Figure S3G). As in the ESCs, Tcf7
was endogenously expressed and stimulated TOPFlash activity
(Figures 3F and S3H), whereas overexpression of Tcf7l1 or
b-catenin-Tcf7l1 fusion repressed TOPFlash activity (Figures
3F and 3G). Repression by Tcf7l1DN and Tcf7l1 HMG* mutants
indicated that inhibition of TOPFlash was caused by a combina-
tion of b-catenin-binding- and DNA-binding-dependent activ-
ities of Tcf7l1 (Figure S3I). These results suggest that the
mechanism of b-catenin-mediated inactivation of Tcf7l1 that
was previously observed in ESCs and mouse embryos also
occurs in human breast cancer.
Tcf7l1 Inactivation Occurs Independently
of Phosphorylation by HIPK2 or NLK
Treating human breast cancer cells with CHIR caused a substan-
tial shift in the mobility of TCF7L1 as analyzed by SDS-PAGEArrowheads point to Lef1-high and Tcf7l1-positive nuclei. The dotted line
denotes the BAT-Gal-positive region. Asterisks mark Tcf7l1-positive cells in
the nearby cornea.
Figure 3. Wnt/b-Catenin Inactivates
TCF7L1 Protein in Poorly Differentiated
Breast Cancer
(A) Heatmap showing relative TCF7L1 mRNA
levels and tumor subtype status from a compen-
dium of 1,211 mammary tumors. Subtypes are
displayed according to previous designations
(Ben-Porath et al., 2008).
(B) Heatmap showing relative TCF7L1 protein
nuclear immunoreactivity for all invasive tumors in
an array of samples from 71 individual patients.
Subtypes are displayed as determined previously
(Khramtsov et al., 2010).
(C) Graphs show the distribution of basal subtype
with respect to the level of TCF7L1 mRNA (left) or
nuclear TCF7L1 protein (right).
(D) Distribution of tumors with nuclear TCF7L1 (n =
15, white), diffuse TCF7L1 (n = 38, black), or low
TCF7L1 (n = 18, gray) classification relative to
the IHC score for cytoplasmic b-catenin for each
individual tumor. Values represent the percentage
of tumors for each TCF7L1 classification display-
ing the indicated cytoplasmic b-catenin IHC score.
(E) TCF7L1 protein (western) and total protein
(Coomassie) for human breast cancer cell lines
treated with vehicle (DMSO) or CHIR (3 mM)
for 12 hr.
(F and G) SuperTOPFlash luciferase reporter
activity for breast cancer cell lines transiently
transfected with the indicated b-catenin-Tcf fusion
plasmid, wild-type Tcf7l1 plasmid, or empty
vector. Values represent mean ± SD of technical
duplicates of biological duplicates.
See also Figure S3.(Figure 3E). Although it is more difficult to detect in mouse ESCs,
likely because of the multiple Tcf7l1 isoforms expressed in ESCs
(Salomonis et al., 2010), this shift also affected endogenous
Tcf7l1 in mouse ESCs treated with CHIR or Wnt3a (Figures 4A,
4B, and S4). Interestingly, work in other systems demonstrated
mobility shifts caused by b-catenin-dependent phosphorylationCell Reportsof Tcf7l1/Tcf3 proteins by homeodo-
main-interacting protein kinase 2 (HipK2)
(Hikasa et al., 2010; Hikasa and Sokol,
2011) and nemo-like kinase (NLK) (Ishi-
tani et al., 1999, 2003). In particular,
HipK2 has been proposed to serve as
a primary mediator of Tcf7l1 regulation
by reducing chromatin binding after
phosphorylation at conserved residues
(Hikasa et al., 2010; Hikasa and Sokol,
2011). We previously showed that Tcf7l1
chromatin occupancy is reduced in
ESCs by Wnt3a, and the reduction
required the Tcf7l1-b-catenin interaction
(Wu et al., 2012a). Therefore, we tested
whether phosphorylation of Tcf7l1 at
conserved residues was needed for
inactivation by using the Tcf7l1-P2/3/4
mutant, which harbors mutations at theresidues phosphorylated by HipK2 and NLK (Hikasa et al.,
2010). Surprisingly, the Tcf7l1-P2/3/4 mutation did not affect
CHIR-induced degradation of Tcf7l1 or Tcf7l1 repression of
target gene expression in ESCs (Figures 4C and 4D). Thus, it is
unlikely that Wnt/b-catenin inactivation of Tcf7l1 in ESC requires
phosphorylation by HipK2 or NLK. In addition, although Tcf7l14, 1–9, July 11, 2013 ª2013 The Authors 5
Figure 4. Inhibition of Chromatin Occupancy Is
Upstream of Tcf7l1 Protein Degradation
(A and B) Western blot analysis of Tcf7l1 protein from
ESCs.
(A) Cells were treated with 15 mM CHIR for 0–2 hr.
(B) Cells were treatedwith 3 mMCHIR for 12 hr and lysates
were treated with 15 U/mL lambda phosphatase.
(C) Tcf7l1 protein from Tcf7l1/ ESC stably expressing
either Tcf7l1-wild-type (Tcf7l1-WT) or Tcf7l1-2/3/4. Cells
were treated with 6 mM CHIR for 18 hr.
(D) SuperTOPFlash assay using Tcf7l1/ ESC tran-
siently transfected with either Tcf7l1-WT or Tcf7l1-2/3/4.
Cells were treated with 3 mM CHIR for 12 hr. Values
represent mean ± SD of technical duplicates of biological
duplicates.
(E) Tcf7l1 protein from lysates of Tcf7l1/ ESC stably
expressing wild-type Tcf7l1. Cells were treated with 3 mM
CHIR and 5 mM MG-132 for 12 hr. Lysates were treated
with 15 U/mL lambda phosphatase.
(F) Quantitative ChIP using anti-Tcf7l1 antibody. Mouse
ESCs were treated for 12 hr with 3 mM CHIR and/or 5 mM
MG-132. qPCR measurements of Tcf7l1-bound DNA are
shown for regions near Axin2, Cdx1, and Mycn genes.
Values represent the mean + SD of percent of precipi-
tated DNA relative to input for duplicate technical mea-
surements of five biological replicates.**p < 0.01; ***p <
0.001; NS, p > 0.05.
(G) Top: Tcf7l1 and Tubulin proteins from lysates of
Tcf7l1/ ESC stably expressing either wild-type Tcf7l1
(WT) or the mutant Tcf7l1 HMG* (HMG*) protein. Cells
were treated with 30 mg/ml cycloheximide. Bottom:
quantitation of western blot and normalization of Tcf7l1
protein levels was calculated for WT (blue) and HMG*
(red) proteins. Each data point represents the mean of
biological triplicates.
(H) Western blot analysis comparing the CHIR-mediated
reduction WT and HMG* Tcf7l1 proteins using the same
ESCs as in (G).
(I) CoIP experiments using anti-Tcf7l1 (top) or anti-
b-catenin (middle). Protein was immunoprecipitated from
lysates of cells treated with 3 mMCHIR and 5 mMMG-132
(bottom).
(J) Quantitative ChIP using anti-b-catenin antibody.
Chromatin was isolated from ESCs treated for 12 hr with
3 mM CHIR and 5 mM MG-132. qPCR measurements of
b-catenin-bound DNA are shown for regions near Axin2
and Cdx1 genes. Values represent the mean + SD of
percent of precipitated DNA relative to input for duplicate
technical measurements of three biological replicates.
See also Figure S4.
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was indeed phosphorylated, we detected no change in phos-
phorylation in the absence or presence of CHIR stimulation.
The CHIR-induced mobility shift of Tcf7l1 was not phosphatase
sensitive, suggesting that it was not mediated by increased
phosphorylation (Figure 4B). The nature of this posttranslational
modification is not known; however, it was blocked by MG-132
(Figure 4E), indicating that it required an active proteasome.
Reduction of Chromatin Occupancy Provides the
Critical Upstream Point of Tcf7l1 Regulation
To elucidate how the reduction of chromatin occupancy is caus-
ally linked to protein degradation, we conducted quantitative
chromatin immunoprecipitation (ChIP) experiments to measure
Tcf7l1 chromatin occupancy following the combined CHIR +
MG-132 treatment. As expected from the changes in Tcf7l1 pro-
tein levels (Figure 1B), CHIR reduced Tcf7l1 occupancy on target
genes (Axin2, Cdx1, and Mycn), and MG-132 increased
occupancy (Figure 4F). Importantly, CHIR treatment reduced
chromatin occupancy even when destabilization of Tcf7l1 was
blocked by MG-132 (Figure 4F), indicating the reduction in
DNA binding was upstream of degradation. Interestingly, since
MG-132 prevented the mobility shift of Tcf7l1 (Figure 4E), this
result also indicates that the reduction of chromatin binding
does not require the posttranslational modification. Combined
with the increased cytoplasmic Tcf7l1 staining after CHIR +
MG-132 treatment (Figure S3G), these data indicate that Tcf7l1
is likely degraded after export from the nucleus.
To examine the role of chromatin occupancy in regulating
Tcf7l1 stability, we used the Tcf7l1 HMG*mutation, which affects
the DNA-binding HMG domain and disrupts DNA binding (Merrill
et al., 2001). The HMG* mutation was sufficient to reduce Tcf7l1
protein stability in the absence of CHIR (Figure 4G). Moreover,
stability of the mutant Tcf7l1 HMG* protein was not substantially
decreased by CHIR (Figure 4H), indicating that destabilization
of Tcf7l1 requires a change in chromatin occupancy. In sup-
port of the model focused on reduction of chromatin occu-
pancy, coimmunoprecipitation (coIP) experiments showed that
Tcf7l1-b-catenin interaction was stimulated by CHIR + MG-132
(Figure 4I), and b-catenin chromatin occupancy increased (Fig-
ure 4J) while Tcf7l1 occupancy decreased (Figure 4F). Together,
these data are most consistent with the notion that the primary
effect of the Tcf7l1-b-catenin interaction is to inhibit chromatin
occupancy. The secondary effect of Tcf7l1 degradation provides
an additional mechanism by lowering Tcf7l1 levels, which further
reduces the amount of Tcf7l1 available to bind to chromatin.
Thus, the combination of reduced DNA binding and Tcf7l1
degradation leads to an additive reduction of Tcf7l1 repression
in response to Wnt/b-catenin activity.
DISCUSSION
The molecular effects of Wnt/b-catenin and Gsk3 inhibition on
Tcf7l1 described here indicate that Tcf7l1 primarily functions
outside of the classic model of canonical Wnt/b-catenin
signaling. In ESCs, inactivation of Tcf7l1 did not require phos-
phorylation of Tcf7l1 at conserved sites, and b-catenin was
sufficient to reduce Tcf7l1 levels without exogenous pathway
stimulation. These results are consistent with a mechanism ofinactivation wherein b-catenin binding inhibits Tcf7l1-repression
by reducing chromatin occupancy, consequently stimulating its
degradation. This mechanism provides a simple explanation for
the controversial pro-self-renewal effects of the b-cateninDC
mutant in ESCs (Kelly et al., 2011; Lyashenko et al., 2011;
Wray et al., 2011): the critical effect of inactivating Tcf7l1 is
stimulated by the b-cateninDC form, thus making b-catenin’s
C-terminal transactivation domain dispensable in ESCs.
Together, the results from experiments using human breast
cancer tumors, breast cancer cell lines, and mouse genetics
indicate that inactivation of Tcf7l1 is the predominant mech-
anism whereby Wnt/b-catenin signaling interacts with this
mammalian Tcf/Lef protein. The viability of Tcf7l1/DN mice
genetically demonstrates that inactivation of Tcf7l1 is the only
effect of Tcf7l1-b-catenin binding that is required for normal
mouse development and life. That said, additional activities
downstream of Tcf7l1-b-catenin interaction likely exist. Indeed,
reporter gene assays support rare Tcf7l1-b-catenin transactiva-
tor activity in some cell types (e.g., 293T, COS7, and human
keratinocytes; Merrill et al., 2001; Slyper et al., 2012; Wu et al.,
2012a); however, the biological significance of this effect
remains to be determined.
Human breast cancer is one important context in which
Tcf7l1-based activation has been suggested (Slyper et al.,
2012). Basal subtype tumors are particularly relevant because
they have been noted to share a gene-expression signature
with ESCs (Ben-Porath et al., 2008) and fetal mammary stem
cells (Spike et al., 2012). These tumors, which express high levels
of Tcf7l1 mRNA, have been suggested to arise following reprog-
ramming to an earlier embryonic stage (Mizuno et al., 2010), and
thus it is important to understand how Wnt/b-catenin and Tcf7l1
function. Previous direct experiments showed that ectopic
Tcf7l1 expression and Wnt3a both stimulate xenograft tumor
formation, mammosphere formation, and colony formation in
Matrigel from breast cancer cell lines (Slyper et al., 2012).
Although it is formally possible that Tcf7l1-b-catenin complexes
may act as transactivators for a set of target genes critical for
breast cancer cells, the data presented here do not support
this possibility. Tcf7l1 displayed only repressor activity in
reporter assay experiments, and Tcf7l1 was degraded following
CHIR treatments. We propose two non-mutually-exclusive pos-
sibilities: (1) Tcf7l1 and Wnt/b-catenin signals mediate parallel
effects, each stimulating tumor cells, and (2) Tcf7l1-b-catenin
complexes have a biochemical activity that is distinct from the
classical transactivator activity. The former possibility is sup-
ported by the recent demonstration of a Wnt/Gsk3/Slug/Snail
signaling axis affecting triple-negative breast cancers (Wu
et al., 2012b).
The effects of b-catenin on Tcf7l1 are most parsimoniously
explained by a mechanism of b-catenin directly inhibiting
Tcf7l1 binding to chromatin. Experiments examining the effects
of b-catenin on the Tcf/Lef interaction with naked DNA showed
little or no effect on binding in vitro, whereas b-catenin interac-
tion significantly affected binding to chromatin by Lef1 (Tutter
et al., 2001). Interestingly, mutational analysis of Lef1 indicated
that an amino terminal region provides intramolecular inhibition
of chromatin binding. b-catenin binding blocks the intramolecu-
lar inhibition, thereby stimulating Lef1 binding to chromatinCell Reports 4, 1–9, July 11, 2013 ª2013 The Authors 7
(Tutter et al., 2001). Although the effect of b-catenin on Lef1 is
different from that predicted for Tcf7l1, these previous findings
demonstrate both positive and negative regulation of chromatin
binding via the b-catenin interaction region of Tcf/Lef proteins.
Further research is necessary to elucidate the biophysical and
biochemical nature of b-catenin’s effects on the chromatin-
binding properties of Tcf7l1.EXPERIMENTAL PROCEDURES
IHC Staining and Scoring of Mammary Tumor Microarray
Quantitative analysis (i.e., scoring) of IHCwas performedwithout knowledge of
specimen identification. Scoring was based on a combination of the intensity
of stained cells and the percentage of tissue. Separate values for nuclear and
cytoplasmic Tcf7l1 immunoreactivity were determined for each sample. Total
Tcf7l1 IHC scores were calculated using a modified Reiner scoring system
(Reiner et al., 1990) by multiplying the intensity of staining (0–3 value) by the
percentage of positive cells. Ranking and scores for b-catenin levels and local-
ization were previously described in Khramtsov et al. (2010).
Statistical Analyses of Tumor RNA and Protein Expression Data
The Kruskal-Wallis test was used to compare the overall effects of stage on
nuclear, cytoplasmic, and total Tcf7l1. The Wilcoxon rank-sum test with Bon-
ferroni correction was used to conduct pairwise comparisons among four
stages. A two-sample t test was used to compare Tcf7l1 mRNA between
basal and nonbasal groups. The Wilcoxon rank-sum test was used to
compare Tc7l1 nuclear, cytoplasmic, and total IHC scores between basal
and nonbasal groups and between luminal A and nonluminal A groups.
Spearman correlations determined the relationships between nuclear Tcf7l1
and cytoplasmic b-catenin; p values < 0.05 were considered statistically
significant.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
four figures and can be found with this article online at http://dx.doi.org/10.
1016/j.celrep.2013.06.001.
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